Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
denosumab
denosumab
| Drug Name | Form | Strength | Non-Formulary | Restricted | Renal Dosing | REMS | Therapeutic Interchange | Notes |
|---|---|---|---|---|---|---|---|---|
| (bbdz) Jubbonti | SOLUTION, SUBCUTANEOUS | bbdz 60 mg/mL | RMH preferred outpatient | |||||
| (bbdz) Wyost | SOLUTION, SUBCUTANEOUS | bbdz 120 mg/1.7 mL | RMH preferred outpatient | |||||
| (bmwo) Osenvelt | SOLUTION, SUBCUTANEOUS | bmwo 120 mg/1.7 mL | ||||||
| (bmwo) Stoboclo | SOLUTION, SUBCUTANEOUS | bmwo 60 mg/mL | RMH preferred outpatient | |||||
| (bnht) Bomyntra | SOLUTION, SUBCUTANEOUS | bnht 120 mg/1.7 mL | RMH preferred outpatient | |||||
| (bnht) Conexxence | SOLUTION, SUBCUTANEOUS | bnht 60 mg/mL | ||||||
| (dssb) Ospomyv | SOLUTION, SUBCUTANEOUS | dssb 60 mg/mL | ||||||
| (nxxp) Bildyos | SOLUTION, SUBCUTANEOUS | nxxp 60 mg/mL | RMH preferred inpatient | |||||
| (nxxp) Bilprevda | SOLUTION, SUBCUTANEOUS | nxxp 120 mg/1.7 mL | RMH preferred inpatient | |||||
| (qbde) Enoby | SOLUTION, SUBCUTANEOUS | qbde 60 mg/mL | ||||||
| (qbde) Xtrenbo | SOLUTION, SUBCUTANEOUS | qbde 120 mg/1.7 mL | ||||||
| Prolia | SOLUTION, SUBCUTANEOUS | 60 mg/mL | ||||||
| Xgeva | SOLUTION, SUBCUTANEOUS | 120 mg/1.7 mL |
Last updated: Feb. 19, 2026
- Black Box Warning: Severe Hypocalcemia in Patients with Advanced Kidney Disease
- Biosimilar Preference List Prolia & Biosimilars: Inpatient preferred is Bildyos
- Biosimilar Preference List Prolia & Biosimilars: Outpatient preferred is Jubbonti or Stobolo
- Biosimilar Preference List Xgeva & Biosimilars: Inpatient preferred is Bilprevda
- Biosimilar Preference List Xgeva & Biosimilars: Outpatient preferred is Osenvelt or Wyost
- REMS: FDA REMS Info
- Restricted: Biosimilar Preference List
Prolia & Biosimilars:
-Inpatient: Bildyos is the preferred biosimilar for inpatient use. Inpatient use is restricted to: Approval by Endocrinology, Nephrology, or Oncology for indication of hypercalcemia in patients who have failed or intolerant to bisphosphonate therapy.
-Outpatient: Jubbonti and Stobolo are the preferred outpatient products. Other products are restricted to use when Jubbonti and Stoboclo are not covered by insurance. Financial review with verification of insurance coverage required before initiating therapy for outpatient administration.
Xgeva & Biosimilars:
-Inpatient: Bilprevda is the preferred biosimilar for inpatient use. Inpatient use is restricted to: Approval by Endocrinology, Nephrology, or Oncology for indication of hypercalcemia in patients who have failed or intolerant to bisphosphonate therapy.
-Outpatient: Osenvelt and Wyost are the preferred outpatient products. Other products are restricted to use when Osenvelt and Wyost are not covered by insurance. Financial review with verification of insurance coverage required before initiating therapy for outpatient administration.